Sinopharm Group Co. Ltd. (Stock Code: 01099) released principal unaudited data for its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord, A shares: 000028; B shares: 200028), concerning the third quarter of 2025.

Sinopharm Accord recorded revenue of RMB18.33 billion for the reporting period, marking a 1.89% year-on-year decrease. Net profit attributable to shareholders reached approximately RMB291.21 million, reflecting a 9.58% drop compared with the same period last year. After excluding non-recurring gains and losses, net profit was RMB280.16 million, down 10.42% year on year.

From the beginning of 2025 through the end of the reporting period, Sinopharm Accord generated total revenue of around RMB55.12 billion, representing a 2.38% decrease from a year earlier. Over the same period, net profit attributable to shareholders was RMB957.12 million, 10.18% lower year on year. Net cash flow from operating activities stood at negative RMB463.08 million, declining by 136.15% compared with the corresponding period in 2024.

Basic earnings per share were RMB1.72 over the first three quarters, and the weighted average return on net assets was 5.29%, decreasing by 0.70 percentage point compared with the prior-year period. As of 30 September 2025, Sinopharm Accord’s total assets rose by 6.31% from year-end 2024 to RMB50.56 billion, while equity attributable to shareholders climbed to around RMB18.43 billion, up 4.30% over the same timeframe.